LifeVantage Q1 FY 2027 Earnings Call - LIFEVANTAGE CORP

Financial Performance:

• Reported Q1 FY2027 (ended Sept 30, 2026) net revenue of $37.1 million, a 22% decline YoY from $47.6 million.
• Revenue decline driven by reduced order frequency, lower average order size, macroeconomic headwinds, and reduced sales from the mind-body GLP-1 system.
• Adjusted EBITDA was $1.9 million (5.2% margin), down from $3.9 million (8.2% margin) in the prior year period.
• Gross margin decreased to 75.4% from 79.5% YoY; adjusted non-GAAP gross margin was 78.2% (excluding inventory allowances for Mind Body line).
• Adjusted non-GAAP net income was $0.6 million ($0.05/share), compared to $2.3 million ($0.18/share) previously.
• Balance sheet remains robust with $13.7 million in cash, zero debt, and a $5 million undrawn revolving credit facility.
• Operating cash flow turned positive at $0.5 million, reversing a $2.3 million outflow in the prior year period due to timing of expenses and inventory/AR reductions.
• Commission and incentive expenses reduced to 41.4% of revenue (from 43.5% YoY); management expects a stabilization range of 41-42% in FY2027.
• Capital expenditures were $1.2 million, primarily for technology infrastructure, with an expected annualized run rate of $3.0–$3.5 million for the next year.
• Announced a new quarterly cash dividend of $0.05 per share, payable Dec 15, 2026, with $58.5 million remaining under the $60 million share repurchase authorization.

Guidance and Future Outlook:

• Management provided no formal financial guidance due to the recent CEO transition and fiscal year-end change.
• Transitioning from a fiscal year ending June 30 to a calendar year starting January 1, 2027, to align strategy and planning.
• Q2 FY2027 will see the launch of a new website and digital platform in North America; Q3 FY2027 will introduce a new consumer-driven business suite for sellers.
• Strategic focus is on stabilizing the business and resetting economics through a more focused, efficient organization rather than immediate growth.
• Expectation to invest in digital transformation and marketing to drive long-term value creation.

Business Segments and Product Lines:

• Americas revenue declined 22.2% to $29 million; Asia-Pacific/Europe revenue declined 21.2% to $8.2 million (including $0.4 million negative FX impact).
• Subscription-based revenue continues to represent over 75% of total revenue, with reported improvements in consultant and customer retention metrics.
• New marketing campaign launching for lead product Protandim NRF2, focusing on activation of natural defense systems against environmental toxins (microplastics, pollution) using visual "before and after" science.
• Product portfolio includes Love Biome (acquired Oct 2025), which partially offset revenue declines.
• New seller toolkit launching in Q3 FY2027, featuring CRM capabilities, AI coaching, social media integration, and training resources to empower independent distributors.

Market and Competitive Landscape:

• Differentiates from competitors by positioning as a "next-generation nutraceutical" company that activates the body's biology rather than merely adding ingredients.
• Aims to capture a "white space" in the market through a consumer-focused, brand-driven approach supported by digital capabilities.
• Competitive strategy involves becoming more selective on market penetration and category focus to maximize potential and efficiency.
• Marketing shift aims to move from traditional distributor reliance to a broader digital ecosystem to acquire and retain direct consumers.

Risks and Challenges:

• Significant 22% revenue decline indicates immediate challenges in consumer demand and order frequency.
• Macro-economic pressures are impacting order sizes and active consumer base behavior.
• Gross margin compression due to higher inventory obsolescence expenses and increased shipping/warehouse costs.
• The transformation strategy involves a complex restructuring of the go-to-market approach and cost structure with no guarantee of immediate results.
• Fiscal year transition creates a six-month reporting period (Jan–Dec 2026) requiring specific 10-K-T filings and potential investor confusion.

Management Commentary and Tone:

• CEO Terrence Moorhead (90-day tenure) expressed a tone of "clear-eyed urgency" balanced with confidence in the company's unique biological science and financial stability.
• Management acknowledged the need for a "comprehensive strategy" to reimagine the business, admitting the current scale does not reflect the company's potential.
• Emphasis placed on the three strategic pillars: Brand repositioning, Business proposition modernization, and Market expansion/focus.
• Confidence expressed in the ability to fund the transformation via existing cash, positive operating cash flow, and no debt.

Analyst Questions and Answers:

• Marketing Channels: New Protandim campaign will initially target the distributor base and existing email lists (500k+ names) before expanding to broader digital channels in the new year.
• Seller Toolkit: The new Q3 product suite is a business management toolkit (CRM, AI coaching, social tools) for distributors, not a new product bundle; AI features are targeted 12-18 months out.
• Cost Structure: New digital investments will be capitalized, while operational efficiencies will be driven by reallocation of SG&A spend to fund growth initiatives.
• Commissions: The 41.4% commission ratio is expected to settle between 41-42% in FY2027, driven by revenue and customer mix dynamics.
• Cash Flow: Positive operating cash flow is expected to be sustainable and more predictable, removing the timing artifacts that skewed the prior year.
• Capital Expenditures: Anticipated annualized CapEx is $3.0–$3.5 million, primarily for e-commerce and the seller business suite.
• Dividends: Clarification provided that the new dividend and all historical dividends are cash-based, not stock.

Other Key Points:

• Foreign currency fluctuations negatively impacted revenue by approximately $400,000 (80 basis points).
• Effective tax rate expected to be 20-25% for the six-month transition period ending Dec 31, 2026.
• The new fiscal year structure aims to streamline strategy, planning, and performance management across the organization.
• The company recorded $12,000 in income tax expense for the quarter.